 |
|
[Alpha Biz=(Chicago) Reporter Kim Jisun] Daewoong Pharmaceutical is predicting good performance in the third quarter. As a result, it is certain that its operating profit will surpass 100 billion won for the first time this year.
According to the securities industry on the 16th, Daewoong Pharmaceutical's third-quarter earnings forecast is 351.5 billion won in sales and 34.3 billion won in operating profit. The figure is up 5.9 percent and 13.9 percent from a year earlier. The cumulative sales are 1.341 trillion won and operating profit is 98.9 billion won.
Daewoong Pharmaceutical's performance in the third quarter was led by Nabota's continued growth and the rapid market settlement of Fexuclue, which was released last year. Nabota is the first domestic botulinum toxin to obtain the US Food and Drug Administration (FDA) item license in 2019. Thanks to the entry into the world's largest botulinum toxin market, Nabota's sales jumped from 50.4 billion won in 2020 to 142 billion won last year. U.S. sales growth has averaged 62 percent annually over the past two years.
It settled in the market by surpassing 10% of the market share in the U.S. last year, raising its export share to 83% in the first half of this year. After recording sales of 75.3 billion won in the first half, it is expected to add 41 billion won in sales in the third quarter and record cumulative sales of 116.3 billion won.
AlphaBIZ 김지선(stockmk2020@alphabiz.co.kr)
